HF
KNTE

HRT Financial’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

HRT Financial’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,405
Closed -$31K – 3315
2023
Q2 		$31K Buy
+10,405
New +$40.1K ﹤0.01% 2061
2022
Q2 		– Sell
-91,703
Closed -$1.03M – 3938
2022
Q1 		$1.03M Buy
+91,703
New +$1.01M 0.01% 999
2021
Q3 		– Sell
-20,213
Closed -$470K – 3898
2021
Q2 		$470K Buy
+20,213
New +$514K ﹤0.01% 1840
2021
Q1 		– Sell
-5,617
Closed -$223K – 3276
2020
Q4 		$223K Buy
+5,617
New +$225K ﹤0.01% 1453

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

HRT Financial's KNTE Position: Q3 2023 in Review

HRT Financial sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 10,405 shares — an estimated $31K sold.

HRT Financial first reported a position in KNTE in Q4 2020 and held it in 4 quarters. The position peaked at $1.03M in Q1 2022. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • HRT Financial reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • HRT Financial sold 10,405 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $31K.
  • HRT Financial first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • HRT Financial's Kinnate Biopharma Inc. Common Stock position peaked at $1.03M in Q1 2022.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on HRT Financial's 13F filing for Q3 2023, filed 13 Nov 2023.